Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $35,400.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the firm's stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $70.80, for a total transaction of $35,400.00. Following the completion of the sale, the vice president directly owned 72,924 shares of the company's stock, valued at approximately $5,163,019.20. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Tuesday, October 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $73.59, for a total transaction of $36,795.00.
• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total transaction of $35,395.00.

ANI Pharmaceuticals Trading Up 0.5%

---

---

Shares of NASDAQ ANIP traded up $0.38 during midday trading on Friday, hitting $71.44. 383,853 shares of the company traded hands, compared to its average volume of 474,006. ANI Pharmaceuticals, Inc. has a 12-month low of $67.14 and a 12-month high of $87.76. The firm has a market cap of $1.62 billion, a P/E ratio of 14.23, a P/E/G ratio of 2.29 and a beta of 0.45. The stock has a 50-day moving average price of $72.32 and a 200 day moving average price of $77.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The company had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. During the same period in the prior year, the firm earned $2.04 earnings per share. ANI Pharmaceuticals's revenue was up 27.6% on a year-over-year basis. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ANIP shares. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a report on Monday, August 10th. Oppenheimer assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a "market perform" rating and a $85.00 target price for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an "outperform" rating and a $104.00 price target on the stock. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Guggenheim raised their price objective on ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a "buy" rating in a research report on Friday, November 6th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $100.00.

Read Our Latest Stock Analysis on ANIP

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Hohimer Wealth Management LLC boosted its stake in shares of ANI Pharmaceuticals by 4.1% during the 3rd quarter. Hohimer Wealth Management LLC now owns 3,638 shares of the specialty pharmaceutical company's stock worth $264,000 after acquiring an additional 142 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company's stock valued at $736,000 after acquiring an additional 143 shares during the period. Commonwealth Equity Services LLC grew its position in shares of ANI Pharmaceuticals by 5.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 3,148 shares of the specialty pharmaceutical company's stock valued at $229,000 after acquiring an additional 150 shares during the period. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 24.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 778 shares of the specialty pharmaceutical company's stock worth $57,000 after purchasing an additional 154 shares in the last quarter. Finally, James Investment Research Inc. increased its stake in shares of ANI Pharmaceuticals by 4.3% in the 3rd quarter. James Investment Research Inc. now owns 4,850 shares of the specialty pharmaceutical company's stock worth $352,000 after purchasing an additional 200 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company's rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

Further Reading

• Five stocks we like better than ANI Pharmaceuticals
• Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
• The Next Big Thing May Not Be One Thing: Inside Lazard's Megatrends ETF
• 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
• Applied Materials Beats and Raises, But Investors Stay Unconvinced

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].